Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.26 - $16.81
Previous CloseN/A
Volume97.81K
Average Volume (3M)918.80K
Market Cap
$1.24B
Enterprise Value$826.40M
Total Cash (Recent Filing)$94.41M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 08, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding85,298,540
10 Day Avg. Volume841,150
30 Day Avg. Volume918,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.15
Price to Cash Flow (P/CF)-15.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit101.81
Enterprise Value/Ebitda-7.14
Forecast
1Y Price Target
$27.63Price Target Upside90.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim data from ASCENT further underscores Yutrepia’s clinical benefits, showing a meaningful improvement in 6-minute walk distance, supporting evidence that higher treprostinil doses translate to better patient outcomes.
Market OpportunityYutrepia will launch into a PAH/PH-ILD opportunity that has grown into a ~$2B market, and should continue expanding to $3B-$4B by 2030 as usage in PH-ILD grows.
Product LaunchLiquidia is ready for the upcoming U.S. launch of Yutrepia following the expected FDA approval for both PAH and PH-ILD.
Bears Say
Competitor ExclusivityLiquidia is on track to launch Yutrepia, its inhaled dry-powder formulation of treprostinil, pending the expiration of Tyvaso DPI’s regulatory exclusivity.
Financial UncertaintyRecent amendment to LQDA's agreement with HealthCare Royalty could provide up to $100M in financing, potentially clearing the path to profitability.
Legal ChallengesThe final legal obstacle for Yutrepia is likely the cross-claim UTHR raised in a lawsuit, but there are low odds of success for UTHR on the challenge.
---
Ownership Overview
36.14% Insiders
5.55% Mutual Funds
0.02% Other Institutional Investors
49.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $8.26 and its highest was $16.81 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $1.24B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 19, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.075.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -0.4.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 85,298,540 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 1.221%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
---
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.63 (90.29% Upside)
$27.63 (90.29% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 19.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.59%
12-Months-Change
Fundamentals
Return on Equity
-209.35%
Trailing 12-Months
Asset Growth
93.61%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
---
LQDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While there were significant strategic advancements and promising clinical trial results, financial challenges and a decrease in revenue were also highlighted.Read More>---
LQDA Stock 12 Month Forecast
Average Price Target
$27.63
▲(90.29% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+42.13%
reiterated a buy rating 4 days ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +42.13% per trade.
---